News

NantKwest and ProMab Biotechnologies announced the establishment of a worldwide license to a B-Cell Maturation Antigen (BCMA) targeted antibody sequence for multiple myeloma along with…
Read More...

Apellis Pharmaceuticals announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals, a global drug development…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the…
Read More...

Pfenex Inc. and Alvogen Ltd. announced entering into agreements expanding their collaboration to develop and commercialize Pfenex’s lead product candidate, PF708, a proprietary…
Read More...

Third Rock Ventures announced the launch of Maze Therapeutics, a company focused on translating genetic insights into new medicines. The company has secured an initial investment…
Read More...

AbCellera announced an expanded collaboration with Denali Therapeutics Inc. to discover antibodies as therapies for neurological indications. AbCellera will generate panels of…
Read More...

Abpro and NJCTTQ announced that they have entered into an agreement to develop multiple novel bispecific antibody therapies in immuno-oncology, including best-in-class T-cell engagers.…
Read More...

Sarepta Therapeutics announced that it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene therapies for…
Read More...

PAREXEL International Corporation announced several new appointments that will enhance the company’s oncology expertise as oncology trials grow in number and complexity. First, PAREXEL…
Read More...

PharmOptima, a member of Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) arm of Genesis Biotechnology Group (GBG), and Ophthy-DS, a preclinical…
Read More...

The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines, have announced a partnership…
Read More...

Amicus Therapeutics announced it is establishing a new Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its commitment to…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III POLO trial. Results from…
Read More...

Imbrium Therapeutics and TetraGenetics announced a strategic research & development collaboration to utilize TetraGenetics’ antibody discovery technology platform (TetraExpress) in…
Read More...

Selexis SA and Turgut Pharmaceuticals (Turgut Ilaclari A.S.) announced that they have signed two commercial license agreements (CLAs) through which Turgut will leverage Selexis’…
Read More...

Amgen, Cytokinetics, Incorporated and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in…
Read More...

Urovant Sciences announced it has entered into a debt financing agreement with Hercules Capital for up to $100 million. Urovant plans to use the proceeds to fund ongoing development of…
Read More...

Ipsen and Clementia Pharmaceuticals announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage clinical asset…
Read More...

Novartis announced that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea…
Read More...

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a…
Read More...